News Releases

Anne Blaes

There are more than 15 million cancer survivors in the world today, each living with the systemic impacts of their cancer treatments. Survivorship research focuses on the myriad of issues cancer treatments cause and seeks to maximize patient quality of life after the therapy.

Hormel Institute

Study of chromosome abnormalities reveals link to cancer

(Austin, Minnesota) – The Hormel Institute, University of Minnesota announces newly published research concerning remnants of ancient viruses found in human chromosomes and how this may affect the risk of developing cancer and other diseases.


Hemangiosarcoma is a highly invasive type of cancer that grows rapidly. It primarily forms in dogs, but can also develop in humans and other animals.

Jaime Modiano with the University of Minnesota College of Veterinary Medicine and Masonic Cancer Center answers questions about what hemangiosarcoma is, the current standard of care, and the implications his cancer research has for veterinary and human medicine.

Hormel Institute

Scientists discover protein’s role in creating a tumor-promoting microenvironment

May 3, 2019 (Austin, Minnesota) – Science is one step closer to eliminating cancer growth in the liver, whether from primary liver cancer or from metastatic tumors from cancers in other areas of the body, thanks to new research published by Dr. Ningling Kang, head of the Tumor Microenvironment and Metastasis lab at The Hormel Institute, University of Minnesota.


Every year the Minnesota Twins hold a Cancer Awareness Night, in which they support a number of local and regional cancer-related organizations through special-edition baseball cap and ticket sales. This year, the Masonic Cancer Center, University of Minnesota is honored to have been chosen as one of the 10 organizations to partner with the team.


On April 30, 2019, the FDA approved Philip Morris’ iQOS, an electronic device that heats instead of burns tobacco, for sale in the United States.


MINNEAPOLIS, MN – A collaborative research team at the University of Minnesota has used Tri-specific killer engagers (TriKE) to target HIV-infected cells in preclinical testing.

The team, led by Jeffrey Miller, MD, Deputy Director of the Masonic Cancer Center, University of Minnesota, and Timothy Schacker, MD, Vice Dean of Research at the University of Minnesota Medical School and Director of the Program In HIV Medicine, has used their combined expertise to now find an innovative approach to potentially cure HIV.


May is Skin Cancer Awareness Month. Skin cancer, including melanoma, is the most common type of cancer in the United States. Melanoma incidence rates in Minnesota have doubled since 1988 for both males and females, according to the Minnesota Department of Health.